Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare rate shifts, dialysis quality scores, and clinical trial liabilities make DaVita’s SEC disclosures some of the most intricate in healthcare. Parsing a 300-page annual report or tracking last-minute 8-K updates can distract from real analysis. Stock Titan solves that problem by converting dense text into plain-English takeaways, so understanding DaVita SEC documents with AI feels effortless.
Whether you need a DaVita annual report 10-K simplified for reimbursement risk, a quick look at the latest DaVita quarterly earnings report 10-Q filing, or an alert on DaVita 8-K material events explained, every disclosure lands here seconds after EDGAR posts. Our platform instantly tags DaVita insider trading Form 4 transactions and streams DaVita Form 4 insider transactions real-time, letting you spot executive moves before the market reacts. AI-powered summaries highlight patient-mix trends, segment margins, and legal contingencies so you can move from document to decision in minutes.
Use these insights to:
- Monitor DaVita executive stock transactions Form 4 ahead of CMS rulings
- Compare dialysis economics with peer benchmarks through our DaVita earnings report filing analysis
- Review the DaVita proxy statement executive compensation to see how incentives align with patient outcomes
DaVita Inc. reported an insider equity transaction by its Chief Compliance Officer. On 12/04/2025, the officer exercised stock appreciation rights covering 5,875 shares of DaVita common stock at a base price of $108.93 per share, receiving shares instead of cash. On the same date, 5,412 shares of common stock were disposed of at $118.25 per share, and an additional 203 shares were withheld at $118.25 per share to cover tax obligations related to the exercise.
After these transactions, the officer beneficially owned 26,298 shares of DaVita common stock in direct form. The stock appreciation rights used in this exercise were originally granted on March 15, 2021 and vested in two equal installments on March 15, 2024 and March 15, 2025.
DaVita Inc. entered into an Eighth Amendment to its existing Credit Agreement, adding a new five-year secured term loan A facility of up to
Borrowings can be made in U.S. dollars, euros, or pounds sterling, with interest based on benchmark rates such as Term SOFR, EURIBOR, or Daily Simple SONIA plus an Applicable Margin. The initial margin is 150 basis points for benchmark-based loans and 50 basis points for Base Rate loans, with both the margin and the undrawn commitment fee later tied to a leverage ratio grid after financial statements for the quarter ending March 31, 2026 are delivered. The new term loan amortizes quarterly starting March 31, 2026, and proceeds are allocated to repay the prior facilities, pay related fees and expenses, and support working capital and general corporate purposes, including potential stock repurchases, acquisitions, and investments.
DaVita Inc. (DVA) director reports stock acquisition. A director of DaVita Inc. reported acquiring 411 shares of the company’s common stock on 11/15/2025 in a transaction priced at $0 per share, as disclosed on a Form 4. Following this transaction, the director beneficially owns 13,981 shares of DaVita common stock, held directly.
DaVita Inc. director reports a small stock acquisition. A DaVita Inc. (DVA) director filed a Form 4 reporting the acquisition of 411 shares of common stock on 11/15/2025 at a reported price of $0 per share. After this transaction, the director holds 411 shares as a direct owner and 2,894 shares as an indirect owner through the Wendy L. Schoppert Revocable Trust. No derivative securities were reported in this filing.
DaVita Inc. director reports a small stock acquisition. A director of DaVita Inc. (DVA) acquired 411 shares of common stock on 11/15/2025 at a reported price of $0 per share, indicating this was likely an equity grant rather than an open-market purchase. Following this transaction, the director beneficially owns 5,110 shares of DaVita common stock, held directly. No derivative securities such as options or warrants are reported as acquired or disposed of in this filing.
A DaVita Inc. (DVA) director reported acquiring 411 shares of common stock on 11/15/2025 at a stated price of $0, indicating this was likely a stock grant rather than an open-market purchase. Following this transaction, the director beneficially owns 2,089 DaVita shares, held in direct ownership. This is a routine insider ownership update showing a modest increase in the director’s equity stake.
DaVita Inc. director reports stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a transaction priced at $0 per share7,231 shares of DaVita common stock in direct ownership. This is a routine insider ownership update, disclosing the director’s latest equity position in the company.
DaVita Inc. director reports small stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a Form 4 filing. The shares were acquired at a stated price of $0, which typically indicates an equity award rather than an open-market purchase. Following this transaction, the director now beneficially owns 6,023 shares of DaVita common stock, held directly.
DaVita Inc. (DVA)11/15/2025 at a reported price of $0. Following this transaction, he is shown as holding 411 shares directly and 13,028 shares indirectly through the Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998. The filing is reported as being made by one reporting person.
DaVita Inc. (DVA) director reports stock acquisition
A director of DaVita Inc. filed a Form 4 reporting the acquisition of 411 shares of common stock on 11/15/2025. The transaction is coded as an acquisition at a stated price of $0, which typically indicates a grant or similar award rather than an open-market purchase. Following this transaction, the reporting person beneficially owns 26,363 shares of DaVita common stock, held in direct ownership. The filing is made by a single reporting person and notes the individual’s role as a Director of the company.
FAQ
What is the current stock price of Davita (DVA)?
What is the market cap of Davita (DVA)?
